Apheresis is a medical technique in which the blood of a patient or donor is extracted and separated into components such as red cells, white cells, plasma, and platelets. Depending on the reason for apheresis, one of these components is isolated and collected by the instrument, while the others are returned to the body.
The global apheresis equipment market is estimated to account for US$ 2,866.4 Mn in terms of value in 2020 and is expected to reach US$ 6,081.8 Mn by the end of 2027.
Global Apheresis Equipment Market: Drivers
Increasing prevalence of leukemia is expected to propel growth of the global apheresis equipment market over the forecast period. For instance, according to Leukemia and Lymphoma Society, 176,200 people in the US are expected to be diagnosed with leukemia, lymphoma or myeloma in 2019.
Moreover, increasing demand for blood is also expected to aid in growth of the market. For instance, according to the study, “The global need and availability of blood products: a modelling study”, published in October 2019, in The Lancet, in 2017, the global blood need was 304?711?244 and the global blood supply was 272?270?243 blood product units.
North America held dominant position in the global apheresis equipment market in 2019, accounting for 43.6% share in terms of value, followed by Asia Pacific and Europe, respectively
Figure 1. Global Apheresis Equipment Market Share (%) in Terms of Value, by Region, 2019
Global Apheresis Equipment Market: Restraints
Inherent high cost of apheresis therapy is expected to hinder growth of the global apheresis equipment market.
Moreover, risks associated with apheresis are also expected to limit growth of the market. Major risks associated with apheresis are:
Global Apheresis Equipment Market: Opportunities
Multiple sclerosis relapses can be treated using apheresis procedures such as therapeutic plasma exchange and immunoadsorption. Thus, increasing prevalence of MS is expected to offer lucrative growth opportunities for the market players. For instance, according to findings published in the journal Neurology in February 2019, the prevalence of MS in 2017 was 362 cases per 100,000, or 913,925 adults.
Moreover, application of therapeutic apheresis in pediatric treatment is also expected to aid in growth of the market. Providing therapeutic apheresis to children is a technologically challenging task. Most of the apheresis therapies are developed from studies and trials on adult patients. However, as the prevalence of diseases such as leukemia and autoimmune disorders is increasing among children, more efforts towards developing new apheresis treatment methods specifically designed for children will serve as a potential opportunity in the market.
The global apheresis equipment market was valued at US$ 2,574.3 Mn in 2019 and is forecast to reach a value of US$ 6,081.8 Mn by 2027 at a CAGR of 11.3% between 2020 and 2027.
Figure 2. Global Apheresis Equipment Market Value, and Y-o-Y Growth (%), 2019-2027
Market Trends/Key Takeaways
Lack of donor availability & histocompatibility is expected to limit growth of the apheresis equipment market in North America. For instance, according to American Red Cross’ June 2019 article, only 3% of people in the U.S. give blood.
Increasing cases of COVID-19 has led regulatory authorities to offer emergency approval for apheresis equipment. For instance, in April 2020, The U.S. FDA issued emergency use authorization to Terumo BCT Inc. and Marker Therapeutics AG for their Spectra Optia Apheresis System and Depuro D2000 Adsorption Cartridge devices.
Global Apheresis Equipment Market: Competitive Landscape
Major players operating in the global apheresis equipment market include, Asahi Kasei Medical Co., Ltd., Terumo BCT, Inc., Fenwal, Inc., Haemonetics Corp., Therakos, Inc., B. Braun Melsungen AG, and HemaCare Corporation.
Global Apheresis Equipment Market: Key Developments
Major players in the market are focused on adopting M&A strategies to expand their product portfolio. For instance, in December 2019, Asahi Kasei Medical Co., Ltd. announced acquisition of Veloxis Pharmaceuticals Inc.
Major players in the market are also focused on product approval and launch to expand their product portfolio. For instance, in October 2019, Mallinckrodt plc and Terumo BCT received regulatory approval for UVADEX (methoxsalen) from Australian Therapeutic Goods. Administration for extracorporeal administration with the THERAKOS CELLEX Photopheresis System.
Apheresis is a procedure of blood purification and blood component separation by using centrifugation or membrane filtration technology. This procedure is performed for blood donation component or for the treatment of disease. In this procedure, the blood is extracted from the patient or from the donor’s body with the help of the apheresis machine and desired blood components are separated on the basis of their molecular size and weight. The remaining blood is transferred back to the patient’s or to the donor’s body. Apheresis procedure is performed for various diseases such as neurological, cardiovascular, renal, autoimmune, hematological and other diseases. The devices used in apheresis procedure are centrifugation and membrane filtration devices. The centrifuge therapeutic apheresis device is used in the separation of plasma or blood components from the whole blood. These devices are automated continuous-flow systems and are used to perform therapeutic plasma exchange, to remove plasma components or fluids, furthermore these devices are used to perform red blood cells exchange.
Restraints of the Global Apheresis Equipment Market
The high cost involved in apheresis treatment, and risks associated with apheresis such as fluid transfer complications, risks of infection, and anticoagulant reactions is expected to challenge growth of the global apheresis equipment market.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.View All Our Clients